Effects of Icaritin on the physiological activities of esophageal cancer stem cells

Han, Songchen; Gou, Yunjiu; Jin, Dacheng; Ma, Jilong; Chen, Meng; Dong, Xinchun

doi:10.1016/j.bbrc.2018.08.060

Cited by 18 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Icaritin is a prenylflavonoid derivative from a traditional Chinese herb, Epimedium Genus. Recently, accumulating studies have demonstrated an anti-tumor effect of icaritin in various cancers, including solid tumors and hematological cancers, such as lung cancer (Zheng et al 2014), hepatocel-lular carcinoma (Sun et al 2015;Hu et al 2016;Lu et al 2017), breast cancer (Guo et al 2011;Tiong et al 2012), esophageal cancer (Han et al 2018), glioblastoma Liu et al 2018), leukemia and lymphoma (Zhu et al 2011;Li et al 2013;Li et al 2014;Wu et al 2015;Zhu et al 2015;Yang et al 2019). Icaritin exerts its anti-tumor effects in various cancers mainly by inhibiting cell proliferation, inducing cell differentiation and apoptosis, suppressing cell migration and invasion (Zheng et al 2014;Xu et al 2015).…”

Section: Introductionmentioning

confidence: 99%

Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway

Xue²,

Zhang³

et al. 2019

gpb

View full text Add to dashboard Cite

Icaritin, a prenylflavonoid derivative from Epimedium Genus, has been reported to exhibit tumor inhibitory effects on many types of tumor cells. Numerous studies have demonstrated that microRNAs (miRs) involve in the biological process of carcinogenesis by controlling expression of their target mRNAs to facilitate tumor growth, invasion, angiogenesis, and immune evasion. miR-124 was reported to involve in the icaritin-induced mitochondrial apoptosis in human carcinoma cells. However, the roles of other miRs in the anti-tumor effects of icaritin and its underlying mechanisms still need to be elucidated. In the present study, realtime-PCR results showed that miR-10a was significantly down-regulated after icaritin treatment in human non-small cell lung cancer cells (A549). Over-expression of miR-10a in A549 cells dramatically abrogated the anti-tumor effects of icaritin on cell proliferation, apoptosis, migration, while suppression of miR-10a partially reproduced the anti-tumor effects of icaritin. Furthermore, we found that the regulation of miR-10a in the anti-tumor effects of icaritin was mediated via the PTEN/AKT/ERK pathway by directly targeting to PTEN. Taken together, miR-10a targets PTEN to mediate the anti-tumor effect of icaritin in A549 cells, which provides a novel insight into the anti-tumor mechanism of icaritin and may provide a new strategy for lung cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway

Xue²,

Zhang³

et al. 2019

gpb

View full text Add to dashboard Cite

show abstract

“…Currently, icaritin has been proven to possess antitumor activity through extensive mechanisms in several cancer cells, which originated from both solid tumor and hematological cancer. The common cytotoxicity of icaritin in different malignancies includes inhibiting proliferation, inducing apoptosis, and blocking cell cycle [11, 17, 18, 20, 21, 23–29, 31, 32, 35–44, 80–83]. These findings indicated icaritin as a wide-spectrum anticancer agent.…”

Section: Discussionmentioning

confidence: 97%

“…Recently, icaritin has attracted great attention in terms of its inhibition of various solid tumors including breast cancer [17–23], hepatocellular carcinoma [24–26], lung cancer [27], oral squamous cell carcinoma [28, 29], endometrial cancer [30, 31], esophageal cancer [32], colorectal cancer [33, 34], glioblastoma [17, 35, 36], ovarian cancer [37], and osteosarcoma [38]. Apart from the common cytotoxic effects, icaritin exhibits some other distinctive properties of restraining tumor progression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy

2019

BioMed Research International

View full text Add to dashboard Cite

Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematological malignancies are still incurable. Therefore, research for novel treatment options was continuing with the natural product as one source. Icaritin is a compound extracted from a traditional Chinese herb,Epimedium Genus, and demonstrated an antitumor effect in various neoplasms including hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In hematological malignancies, icaritin showed multiple cytotoxic effects to induce apoptosis, arrest the cell cycle, inhibit proliferation, promote differentiation, restrict metastasis and infiltration, and suppress the oncogenic virus. The proved underlying mechanisms of the cytotoxic effects of icaritin are different in various cell types of hematological malignancies but associated with the critical cell signal pathway, including PI3K/Akt, JAK/STAT3, and MAPK/ERK/JNK. Although the primary target of icaritin is still unspecified, the existing evidence indicates that icaritin is a potential novel therapeutic agent for neoplasms as with hematological malignancies. Here, in the field of hematology, we reviewed the reported activity of icaritin in hematologic malignancies and the underlying mechanisms and recognized icaritin as a candidate for therapy of hematological malignancies.

show abstract

“…ICT exhibits an extensive range of biological and pharmacological activities, such as neuroprotection (Wang et al., 2009 ), cardiac protection (Zhu & Lou, 2005 ; Wo et al., 2008 ; Wang et al., 2009 ; Zhang et al., 2015 ), anti-inflammation, immunomodulation (Li et al., 2012 ; Lai et al., 2013 ; Liao et al., 2016 ), and multidrug resistance reversal activity (Liu et al., 2009 ). Increasing studies proved ICT could suppress growth of different kinds of cancers including breast cancer (Wang & Lou, 2004 ; Guo et al., 2011 ; Tiong et al., 2012 ), prostate cancer (Huang et al., 2007 ; Sun et al., 2015 ; Hu et al., 2016 ; Sun et al., 2016 ), bladder cancer (Pan et al., 2016 ), endometrial cancer (Tong et al., 2011 ), glioblastoma (Han et al., 2015 ; Li et al., 2016 ), colorectal cancer (Li et al., 2016 Zhou et al., 2016 ; Zhou et al., 2017 ), lymphoma (Li et al., 2014 ; Wu et al., 2015 ), hepatocellular carcinoma (He et al., 2010 ; Sun et al., 2013 ; Zhao et al., 2015 ; Zhang et al., 2016 ; Lu et al., 2017 ), lung cancer (Zheng et al., 2014 ; Wang et al., 2015 ), osteosarcoma (Wang & Wang, 2014 ), chronic/acute myeloid leukemia (Zhu et al., 2011 ; Li et al., 2013 ), esophageal cancer(Han et al., 2018 ) and hematological malignancies (Li et al., 2013 ; Zhu et al., 2015 ). Ye and Lou's researches have proved that ICT could induce the proliferation of estrogen receptor (ER)-positive breast cancer MCF-7 cells at sub-micromolar levels.…”

Section: Introductionmentioning

confidence: 99%

A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Icaritin (ICT) and hydrous icaritin (HICT) are two similar flavonoids compounds isolated from Epimedium Genus. This is the first comparative study on their in vitro and in vivo antitumor effects. Nanorods (NRs) were prepared for ICT and HICT by anti-solvent precipitation method using D-alpha tocopherol acid polyethylene glycol succinate (TPGS) as a stabilizer. The prepared ICT-NRs and HICT-NRs had similar diameter (155.5 nm and 201.7 nm), high drug loading content (43.30 ± 0.22% and 41.08 ± 0.19%), excellent stability and a similar sustaining drug release manner. Nanorods improved the in vitro toxicity against 4 different cancer cells in contrast to free ICT or free HICT; however, no significant difference was observed in this regard between ICT-NRs and HICT NRs. In the in vivo study on the anticancer efficacy on MCF-7 and PLC/PRE/5 tumor-bearing mice model, HICR-NRs displayed certain advantage over ICT NRs with higher tumor inhibition rate.

show abstract

Effects of Icaritin on the physiological activities of esophageal cancer stem cells

Cited by 18 publications

References 17 publications

Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway

Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway

Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy

A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods

Contact Info

Product

Resources

About